On TikTok, Reddit, and some telehealth websites, microdosing glucagon-like peptide-1 (GLP-1) receptor agonist medications is pitched as a gentler, more flexible way to use drugs such as the GLP-1 agonist semaglutide (Ozempic, Wegovy), the dual GIP/GLP-1 agonist tirzepatide (Mounjaro, Zepbound), and oral nonpeptide GLP-1 receptor agonist orforglipron (Foundayo)
Brand-name Wegovy at $1,000 to $1,400 per month versus Peak Wellness at $149 per month on the annual plan means many patients simply cannot access brand-name versions
The broader 2026 context matters: as of May 2026, the FDA has proposed regulatory changes affecting compounded semaglutide and tirzepatide, with a public comment period closing June 29, 2026
After this date, the medication may begin to lose its strength or stability, its potency or effectiveness, and in some cases, its chemical composition could begin to change, which means it may not work as intended
We are happy to support you to stop taking a GLP-1
Im proud I listened to my body
